UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of clinical oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 235 - 244
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | General aspects | Medical sciences | Tumors | Prospective Studies | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Maximum Tolerated Dose | Phthalazines - therapeutic use | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Aged | Genes, BRCA1 | Antimitotic agents | Dosage and administration | Antineoplastic agents | Drug therapy | Testing | Ovarian cancer | Medical research | Breast cancer | Mutation | Index Medicus | Abridged Index Medicus | Anemia | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 245 - 251
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | General aspects | Medical sciences | Female genital diseases | Tumors | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - genetics | Maximum Tolerated Dose | Phthalazines - therapeutic use | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Aged | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Antimitotic agents | Dosage and administration | Antineoplastic agents | Drug therapy | Testing | Ovarian cancer | Chemotherapy | Breast cancer | Mutation | Cancer therapies | Index Medicus | Abridged Index Medicus | Anemia | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Cancer science, ISSN 1347-9032, 03/2019, Volume 110, Issue 3, pp. 1064 - 1075
toxicity | pharmacokinetics | poly(ADP‐ribose) polymerase | fluzoparib | antitumor activity | poly(ADP-ribose) polymerase | Life Sciences & Biomedicine | Oncology | Science & Technology | DNA Repair - drug effects | Apoptosis - drug effects | Humans | Rats | Clinical Trials as Topic | Xenograft Model Antitumor Assays - methods | Piperazines - pharmacology | Rats, Sprague-Dawley | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Poly(ADP-ribose) Polymerases - metabolism | Animals | DNA Breaks, Double-Stranded - drug effects | Mice, Nude | Cell Line, Tumor | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Clinical trials | DNA damage | Sugars | Monosaccharides | Cell proliferation | Homologous recombination | Cytotoxicity | Metastasis | Kinases | Cancer therapies | DNA repair | Stomach cancer | Defects | Ovarian cancer | Homologous recombination repair | Enzymatic activity | Ribose | Paclitaxel | Xenografts | Drug dosages | Deoxyribonucleic acid--DNA | Enzymes | Poly(ADP-ribose) polymerase | Breast cancer | FDA approval | Poly(ADP-ribose) Polymerase 1 | Antitumor activity | Hypoxia | Software | Apoptosis | Pharmaceuticals | Index Medicus | Original
Journal Article
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 512 - 518
Breast cancer | Olaparib | PARP-inhibitors | BKM120 | Ovarian cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Phosphoinositide-3 Kinase Inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Aminopyridines - pharmacokinetics | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasm Grading | Germ-Line Mutation | Adult | Female | Piperazines - pharmacokinetics | Ovarian Neoplasms - drug therapy | Aminopyridines - administration & dosage | Phthalazines - administration & dosage | Morpholines - administration & dosage | Breast Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | BRCA1 Protein - genetics | Breast Neoplasms - genetics | Poly(ADP-ribose) Polymerases - genetics | Breast Neoplasms - pathology | Neoplasm Recurrence, Local - genetics | Aged | Morpholines - pharmacokinetics | BRCA2 Protein - genetics | Index Medicus | ovarian cancer | Editor's Choice | olaparib | breast cancer | Original
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 04/2015, Volume 33, Issue 12, pp. 1397 - 1406
Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms, Glandular and Epithelial - enzymology | Clinical Trials, Phase III as Topic | Animals | Humans | Enzyme Inhibitors - pharmacology | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Enzyme Inhibitors - therapeutic use | Ovarian Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Index Medicus | Bon | Biology of Neoplasia
Journal Article
Science (American Association for the Advancement of Science), ISSN 0036-8075, 03/2017, Volume 355, Issue 6330, pp. 1152 - 1158
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Poly(ADP-ribose) Polymerase Inhibitors - chemistry | Humans | Antineoplastic Protocols | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Synthetic Lethal Mutations | DNA Repair - genetics | Antineoplastic Agents - chemistry | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | DNA Damage - genetics | Germ-Line Mutation | Antineoplastic Agents - pharmacology | Ubiquitin-Protein Ligases - genetics | BRCA2 Protein - genetics | Complications and side effects | Chemical inhibitors | Care and treatment | Methods | Cancer | Drugs | BRCA2 protein | BRCA1 protein | DNA polymerase | Poly(ADP-ribose) | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Lethality | DNA repair | Inhibitors | Ribose | Genetics | Mutation | Repair | Deoxyribonucleic acid--DNA | Tumors | Index Medicus | Therapy | Defects
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 882 - 892
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Male | Ovarian Neoplasms - genetics | Tissue Distribution | Prostatic Neoplasms - genetics | Neoplasms - genetics | Adult | Female | Piperidines - pharmacokinetics | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Neoplasm Recurrence, Local - diagnosis | Mutation - genetics | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | BRCA1 Protein - genetics | Maximum Tolerated Dose | Indazoles - pharmacokinetics | Piperidines - therapeutic use | Heterozygote | Neoplasm Recurrence, Local - genetics | Aged | Neoplasms - pathology | BRCA2 Protein - genetics | Indazoles - therapeutic use | Cohort Studies | Cancer patients | Analysis | Genetic aspects | Genetic transcription | Sugars | Cancer | Monosaccharides | Index Medicus
Journal Article